Gyre Therapeutics Q3 2024 revenue down 20% to $25.5M; net income falls to $2.9M from $7.5M

GYRE THERAPEUTICS, INC.

2024-Q3 EPS reported $0.05 revenue$77,885,000

Revenue $25.5M in Q3 2024 vs $32.0M in Q3 2023, down 20% due to lower anti-fibrosis drug sales.
Net income $2.9M in Q3 2024 vs $7.5M in Q3 2023; nine-month net income $17.3M vs $15.5M.
Phase 3 trial for F351 in CHB liver fibrosis completed; topline data expected Q1 2025. US Phase 2 for MASH in 2025.
Commercial launches of avatrombopag (H1 2025) and nintedanib (2025) in China expected.
Cash and equivalents $15.9M as of Sept 30, 2024; funding runway over 12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.